ITMCTR2000003320Completed未知
A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)
Trial Snapshot
- Phase
- 未知
- Status
- Completed
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Patients with confirmed new coronavirus-infected pneumonia;
- •2. Aged >=18 years old;
- •3. Voluntarily sign written informed consent.
Exclusion Criteria
- •1. Severe pneumonia requires mechanical ventilationcritically severe cases;
- •2. Estimated Time of Death is less than 48 hours;
- •3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease,and abnormal lung development;
- •4. Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;
- •5. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;
- •6. Mental state unable to cooperate, suffering from mental illness, unable to control, unable to express clearly
- •7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;
- •8. Patients with a history of substance abuse or dependence;
- •9. Pregnant or lactating women;
- •10. Patients who participated in other clinical trials within the last 3 months;
- •11. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.
Investigators
Similar Trials
Recruiting
Phase 4
A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19)ovel Coronavirus Pneumonia (COVID-19)ITMCTR2000002975Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Recruiting
Phase 4
A randomized, open-label, blank-controlled, multi-center clinical study for Lian-Hua Qing-Wen Capsule/Granule in the treatment of asymptomatic patients with novel coronavirus pneumoniaITMCTR2100004336Hebei Province Chest Hospital
Recruiting
Phase 4
A randomized, open-label, blank-controlled, multi-center clinical study for Lian-Hua Qing-Ke Tablets in the treatment of severe novel coronavirus pneumoniaovel Coronavirus Pneumonia (COVID-19)ITMCTR2100004363Hebei Province Chest Hospital
Active, not recruiting
Phase 1
A Study of the Safety of Intravenous Brincidofovir for Adenovirus InfectioTreatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipientsMedDRA version: 20.1 Level: PT Classification code 10060931 Term: Adenovirus infection System Organ Class: 10021881 - Infections and infestationsEUCTR2017-003984-37-ESChimerix, Inc30
Active, not recruiting
Phase 1
A Study of the Safety of Intravenous Brincidofovir for Adenovirus InfectioTreatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipientsMedDRA version: 21.1Level: PTClassification code 10060931Term: Adenovirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-003984-37-ITCHIMERIX, INC.30